title: [Heart failure with preserved ejection fraction (diastolic heart failure)].
abstract: Diastolic heart failure, which is also called as heart failure with preserved ejection fraction, is a clinical syndrome in which patients have signs and symptoms of heart failure, normal or near normal left ventricular ejection fraction (≥ 50%) and evidence of diastolic dysfunction. Recent epidemiological studies have demonstrated that more than half of all heart failure patients have diastolic heart failure. The syndrome is more common in women than in men and the prevalence increases with age. Patients with diastolic heart failure form a fairly heterogeneous group with complex pathophysiologic mechanisms. The disease is often in association with other comorbidities, such as hypertension, diabetes mellitus or obesity. The diagnosis of diastolic heart failure is best achieved by two-dimensional and Doppler echocardiography, which can detect abnormal myocardial relaxation, decreased compliance and increased filling pressure in the setting of normal left ventricular dimensions and preserved ejection fraction. Unlike heart failure with reduced ejection fraction, there is no such an evidence-based treatment for heart failure with preserved ejection fraction, which would improve clinical outcomes. Thus, pharmacological therapy of diastolic heart failure is based mainly on empiric data, and aims to the normalization of blood pressure, reduction of left ventricular dimensions and increased heart rate, maintenance of normal atrial contraction and treatment of symptoms caused by congestion. Beneficial effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers may be utilized in patients with diastolic dysfunction, especially in those with hypertension. Beta-blockers appear to be useful in lowering heart rate and thereby prolonging left ventricular diastolic filling time, while diuretic therapy is the mainstay of treatment for preventing pulmonary congestion. Nonetheless, treatment of the underlying disease is also an important therapeutic approach. This review summarizes the state of current knowledge with regard to diastolic heart failure.
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Kardiológiai Intézet Debrecen Móricz Zs. krt. 22. 4032. iczuriga@med.unideb.hu
authors.forename: István
authors.initials: I
authors.lastname: Czuriga
authors.forename: Attila
authors.initials: A
authors.lastname: Borbély
authors.forename: Dániel
authors.initials: D
authors.lastname: Czuriga
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Papp
authors.forename: István
authors.initials: I
authors.lastname: Edes
mesh_terms: D000367:Age Factors; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D005260:Female; D054144:Heart Failure, Diastolic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D008297:Male; D012737:Sex Factors; D013318:Stroke Volume
chemical_list: D002317:Cardiovascular Agents